Description
MODIFICATION TO DEOBLIGATE EXCESS FUNDS FOR CLOSEOUT-BASE YR
Base award description: RADIO PHARMACEUTICALS
Modification chain · 10 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2018-06-20+$102,000= $102,000
- Mod P000022019-06-12+$105,000= $207,000
- Mod P000032020-06-22+$70,000= $277,000
- Mod P000042020-06-30+$52,500= $329,500
- Mod P000052020-12-29+$52,500= $382,000
- Mod P000062021-06-29+$112,000= $494,000
- Mod P000072022-09-21-$12,200= $481,800
- Mod P000082022-09-21-$67,200= $414,600
- Mod P000092022-09-21-$3,500= $411,100
- Mod P000102023-02-07-$88,000= $323,100
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2018-06-20 | +$102,000 | $102,000 | RADIO PHARMACEUTICALS |
| Mod P00002· EXERCISE AN OPTION | 2019-06-12 | +$105,000 | $207,000 | RADIO PHARMACEUTICALS |
| Mod P00003· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-06-22 | +$70,000 | $277,000 | RADIO PHARMACEUTICALS |
| Mod P00004· EXERCISE AN OPTION | 2020-06-30 | +$52,500 | $329,500 | RADIO PHARMACEUTICALS |
| Mod P00005· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-12-29 | +$52,500 | $382,000 | RADIO PHARMACEUTICALS CORRECTION TO OPTION YEAR 2 MOD P00004 |
| Mod P00006· EXERCISE AN OPTION | 2021-06-29 | +$112,000 | $494,000 | RADIO PHARMACEUTICALS OPTION YEAR 3 (07/01/2021 - 06/30/2022) EXTENSION |
| Mod P00007· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-09-21 | −$12,200 | $481,800 | MODIFICATION TO DEOBLIGATE EXCESS FUNDS FOR CLOSEOUT |
| Mod P00008· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-09-21 | −$67,200 | $414,600 | MODIFICATION TO DEOBLIGATE EXCESS FUNDS FOR CLOSEOUT |
| Mod P00009· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-09-21 | −$3,500 | $411,100 | MODIFICATION TO DEOBLIGATE EXCESS FUNDS FOR CLOSEOUT |
| Mod P00010· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2023-02-07 | −$88,000 | $323,100 | MODIFICATION TO DEOBLIGATE EXCESS FUNDS FOR CLOSEOUT-BASE YR |
Related awards · 10
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI JNM4NBNHFE66)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25526N0132 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS | $1,200,000 | FY2026 |
| 36C26026N0121 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $996,874 | FY2026 |
| 36C24926N0263 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $823,062 | FY2026 |
| 36C25525N0282 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS | $166,146 | FY2025 |
| 36C25525N0176 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS | $1,362,395 | FY2025 |
| 36C25225F0044 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $631,354 | FY2025 |
Other recipients under 3650 from 245-NETWORK CONTRACT OFFICE 5 (36C245) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24519F0696 | UNITED THERAPEUTICS CORP | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $11,269 | FY2019 |
| 36C24519F0682 | ARIAD PHARMACEUTICALS, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $0 | FY2019 |
| 36C24519F0619 | UNITED THERAPEUTICS CORP | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $11,269 | FY2019 |
| 36C24518F3643 | CHUDY GROUP LLC | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $393,614 | FY2018 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24518P3451_3600_-NONE-_-NONE- · retrieved 2026-09-26.